Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC

Who May Qualify: - Gender unrestricted, age 18-75 years; - HCC conforms to AASLD or EASL clinical diagnostic standards; - HCC Barcelona Clinic Liver Cancer (BCLC) staging is C, with at least one measurable tumor in the liver (longest diameter ≥1cm); - Liver function Child-Pugh Class A or Class B with a score of 7; - ECOG score of 0-1; - Platelet count ≥60×10\^9/L, PT time prolongation ≤6 seconds. Who Should NOT Join This Trial: - Irreversible coagulation dysfunction, with obvious bleeding tendency; - Patients who need long-term anticoagulation or antiplatelet treatment and cannot stop medication; - Patients with unstable or active ulcers, gastrointestinal bleeding; - Patients with untreated heart disease or poorly controlled hypertension as judged by the researcher; - Severe dysfunction of important organs, such as severe cardiopulmonary dysfunction; - Patients with hepatic encephalopathy or refractory ascites requiring treatment; - Human weakened immune system Virus (HIV) infection; - Active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection (activity defined as viral load \> 20000 IU/mL), or HBV, HCV positive patients who refuse to accept standardized antiviral treatment; - Inability to swallow oral medication. - Gastrointestinal diseases that may affect the absorption or tolerance of the study medication. - History of corneal epithelial cysts or other causes of blurred vision, or medical abnormalities found in ophthalmic screening. - Known allergy to VIC-1911 or its components. - Within 4 weeks before the study, radiotherapy or interventional therapy for the disease under study was performed; - Other concurrent antitumor treatments; - The researcher assesses that the patient cannot or is unwilling to comply with the requirements of the study protocol. Always talk to your doctor about whether this trial is right for you.